Recent data have suggested that protocols combining the radiosensitizer, misonidazole (MISO), with bifunctional alkylating agents and several nitrosoureas may be useful for the treatment of human malignancies (Clement et al., 1980; Law et al., 1981; Martin et al., 1981; Mulcahy et al., 1981; Rose et al., 1980; Siemann, 1981; Siemann & Sutherland, 1982; Tannock, 1980; Twentyman, 1981) . Several mechanisms have been proposed to explain the interaction observed between MISO and these chemotherapeutic agents (for reviews -see McNally, 1982; Brown, 1982; Siemann, 1982) . These mechanisms include: (1) the additive effects of killing hypoxic cells with MISO and oxic cells with chemotherapeutic agents, (2) the alteration of the chemotherapeutic agent pharmacokinetics by MISO, (3) the effects of MISO on the recovery from drug-induced potentially lethal damage (PLD), and (4) the manifestations of the "preincubation effect" observed in vitro.
In vitro "pre-incubation" or "co-incubation" studies have clearly demonstrated a requirement for metabolism of the sensitizer under hypoxic conditions to observe chemopotentiation (Stratford et al., 1980; Roizin-Towle & Hall, 1981; Mulcahy & Dembs, 1983; Siemann et al., 1984) . Direct evidence for such a requirement in solid tumours is lacking.
Indirect evidence using tumours of different sizes (and different hypoxic fractions) does suggest that hypoxic cells may be required for the interaction between MISO and various chemotherapeutic agents (Martin et al., 1981; Spooner et al., 1982) , but other explanations may also be feasible (Siemann, 1982) . In an attempt to provide more direct evidence for the role of hypoxic cells in chemopotentiation, i.c. and unclamped or clamped s.c. 9L tumours were treated with combinations of MISO and either BCNU or CCNU. Intracerebral 9L tumours have been shown to contain no hypoxic cells Wheeler et al., 1984) , and 30mg to -2000mg s.c. 9L tumours are thought to contain no hypoxic cells Wheeler et al., 1984) . In addition, i.c. 9L tumours have been shown to exhibit no recovery from either BCNU-or CCNU-induced PLD (Rosemblum et al., 1975b (Rosemblum et al., , 1976 (Rosemblum et al., , 1977 , so mechanistically the requirement for hypoxic cells can be separated from inhibition of recovery from drug-induced PLD in this study.
Materials and methods

In situ tumour systems
The origin of the 9L cell line (Schmidek et al., 1971; Wheeler et al., 1984) , the methods for maintaining the cells in culture , the implantation procedures for i.c. (Barker et al., 1973; Wheeler et al., 1979) and s.c. tumours, and the in situ growth characteristics CCNU (4, 8, 12, 16, or 20mgkg-1) either alone or simultaneously with 2.5 mmol kg-1 (0.5mg kg-1) of MISO. After 20-24 h, the rats were killed by cervical dislocation, the tumours removed and assayed for colony formation as previously described (Rosenblum et al., 1975a; Wallen et al., 1980) . Tumours from rats injected with saline, MISO alone or HPMC were handled similarly and assayed in each experiment. An amount of saline equivalent to that injected in the combined protocols was always given simultaneously with the single agent treatments, so the volume of fluid/kg body wt remained constant for each treatment.
Clamped experiments Rats bearing s.c. tumours were anaesthetized with sodium pentobarbital and then injected with either saline or MISO. After 30 min the tumours were tightly clamped with a plastic, double-soft jaw, handless vascular clamp (Stewart et al., 1983 (Siemann et al., 1984) . In both i.c. (Figure 1) and unclamped s.c. (Figures 2 and 3 ) tumours, MISO combined with either BCNU or CCNU produced no additional cell kill. For comparison, the BCNU dose response data (X's) of Rosenblum et al. (1975b) is shown in Figure 1 .
When s.c. 9L tumours were clamped 30 min after injection of 2.5mmolkg-1 of MISO, then 2h later the clamps released and either 3 mg kg-1 or 6mg kg-1 of BCNU injected, a significant (P<0.01) increase in cell kill over that of the appropriate controls was observed (Table I ). An increase in cell kill that was not statistically (P>0.05) different from the appropriate controls hypoxic conditions in a manner similar to that reported by others (Stratford et al., 1980; RoizinTowle & Hall, 1981; Mulcahy & Dembs, 1983 in the drug combination may not have been optimal since in most tumour systems MISO has been significantly more effective at enhancing the efficacy of CCNU than of BCNU (e.g., Siemann & Mulcahy, 1982) . The absence of a shoulder on the BCNU alone dose response curve for the i.c. 9L tumours might prevent a MISO-BCNU interaction from being observed because MISO has been shown to be particularly effective at removing the shoulder on the drug dose response curve (Stratford et al., 1980; Roizin-Towle & Hall, 1981; Siemann et al., 1984) . If the mechanism by which MISO potentiates the cell killing effects of BCNU is inhibition of recovery from BCNUinduced PLD, MISO may not be able to potentiate the effects of BCNU in i.c. 9L tumours because no recovery from BCNU-induced PLD occurs (Rosenblum et al., 1975b (Rosenblum et al., , 1976 (Rosenblum et al., , 1977 . Finally, if metabolism of MISO by hypoxic cells is required to obtain a MISO-BCNU interaction on i.c. 9L tumours, no interaction would be expected because i.c. 9L tumours contain no hypoxic cells Wheeler et al., 1984) .
To distinguish among these possibilities, similar experiments were performed on s. Finally, as has been argued previously from radiation studies . the present data support the hypothesis that s.c. 9L tumours contain no hypoxic cells. Therefore, the intermediate radiation dose response curve previously reported for s.c. 9L tumours must be generated by as yet undefined factors that could be ultimately important for limiting the radiocurability of tumours.
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